Lilly raises outlook for third time this year as Zepbound sales soar.
The drug continues do dominate the market for prescription weight-loss drugs in the U.S.
Original Source
Read the full article at Marketwatch →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.